Iovance Biotherapeutics Inc

IOVA

Equity

ISIN null / Valor 37313485

NASDAQ (2026-09-03)

USD 8.70+0.93%

Iovance Biotherapeutics Inc
UMushroom community rating:

4.40 3 votes No rating yet

NegativeNeutralPositive

About company

Iovance Biotherapeutics is a clinical-stage biotechnology company developing adoptive cell therapies based on tumor-infiltrating lymphocytes (TILs) to treat solid tumors. The company’s platform harvests a patient’s own tumor-infiltrating T cells, expands and activates them ex vivo, and returns them to the patient with the goal of generating durable anti-tumor immune responses; its most advanced programs include lifileucel (LN-144) for advanced melanoma and LN-145 and related TIL candidates being evaluated in HPV-associated and other solid tumors. Iovance operates its own manufacturing network to support clinical supply and scale-up, runs multiple registrational and earlier-stage trials across tumor types, and is a Nasdaq-listed company pursuing regulatory milestones and commercial readiness while partnering selectively to broaden development and access.

Summarized from source with an LLMView SourceSector: Technology

Revenue and product mix

Total product revenue in 1Q26 was ~$71.4M, up ~45% versus 1Q25; U.S. Amtagvi contributed about $60M and global Proleukin about $11M.

Guidance

Iovance guided 2Q26 total product revenue of $86M–$88M and full-year 2026 product revenue of $350M–$370M; U.S. Amtagvi revenue for 2Q26 is expected to be $79M–$81M.

Profitability metrics

Gross margin was 41%, which absorbed one‑time costs related to annual iCTC maintenance and a recent facility expansion; management expects manufacturing efficiencies and cost reductions to improve margins in 2026–2027.

Expenses, net loss and EPS

R&D spending declined (R&D down 12% vs. 4Q25 and the third consecutive quarter of improvement). Net loss for 1Q26 was $79.0M (EPS -$0.19) versus a $116.2M loss (EPS -$0.36) in 1Q25.

Cash position

Cash, cash equivalents, short-term investments and restricted cash totaled roughly $319M as of March 31, 2026; the company expects current cash plus expense reductions to fund operations well into 2028.

Commercial and manufacturing progress

Iovance centralized manufacturing at the Iovance Cell Therapy Center (iCTC), expanded the facility to reduce maintenance-related supply interruptions, reports a commercial turnaround time of 32 days or less for Amtagvi, and has a network of >90 authorized treatment centers (targeting ≥110 by year-end 2026).

Clinical and pipeline highlights

Notable clinical updates include a confirmed objective response rate (cORR) of 40% (first five evaluable patients) and 100% disease control in metastatic serous endometrial cancer (IOV-END-201), positive early sarcoma signals (cORR 50% in initial UPS/DDLPS patients) and ongoing registrational trials including IOV-LUN-202 (NSCLC) and TILVANCE-301 (frontline melanoma); several next‑generation programs (IOV-5001, IOV-4001, IOV-3001) are advancing.

Regulatory and IP updates

Iovance expects MAA decisions in Australia (H1 2026) and Switzerland (H1 2027), withdrew and will promptly resubmit a UK MAA for procedural reasons, plans an EMA resubmission in 2026, and holds a broad patent portfolio providing expected exclusivity into 2042 for Amtagvi.

Summarized from source with an LLMView Source

Key figures

294%1Y

41.5%3Y

-65.3%5Y

Performance

91.6%1Y

96.6%3Y

94.3%5Y

Volatility